Turkish Journal of Gastroenterology
Original Article

Tenofovir–best hope for treatment of chronic hepatitis B infection?

1.

Department of Gastroenterology, Ankara University Faculty of Medicine, Ankara, Turkey

2.

Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara, Turkey

3.

Department of Infectious diseases, Yıldırım Beyazıt University Faculty of Medicine, Ankara, Turkey

4.

Department of Infectious Diseases, Ankara University Faculty of Medicine, Ankara, Turkey

5.

Department of Gastroenterology, Dışkapı Yıldırım Beyazıt Education and Research Hospital, Ankara, Turkey

6.

Department of Gastroenterology, Hacettepe University Faculty of Medicine, Ankara, Turkey

7.

Department of Gastroenterology, Dışkapı Yıldırım Beyazıt Education and Research Hospital, Ankara, Turkey; Department of Gastroenterology, Yıldırım Beyazıt University Faculty of Medicine, Ankara, Turkey

Turk J Gastroenterol 2015; 26: 322-327
DOI: 10.5152/tjg.2015.0164
Read: 558 Downloads: 107 Published: 25 July 2019

Abstract

Background/Aims: To evaluate the effectiveness of tenofovir in patients with chronic hepatitis B infection in a real life setting.

 

Materials and Methods: We performed a retrospective analysis of data from 164 patients with chronic hepatitis B who were treated with Tenofovir. Eighty-six patients (52.4%) were naïve. Seventy-seven (46.9%) patients were previously treated with anti-viral drugs, including standard interferon (n=4), pegylated (PEG) interferon (n=14), standard interferon together with lamivudine (n=13), lamivudine alone (n=41), adefovir (n=2), lamivudine together with adefovir (n=1), and entecavir (n=2). Six patients (3.7%) had liver cirrhosis before treatment of tenofovir.

 

Results: The patients who have hepatitis B viral DNA>104 copy/mL with chronic hepatitis B infection were included in the treatment of Tenofovir. Average follow up time was 30.31±14.33 months. HBV DNA negativity and alanine aminotransferase (ALT) normalization were 86.5% and 71.3%, respectively, at the last visit. Hepatitis B e-Antigen (HBeAg) seroconversion occurred in 11 (19.6%) out of 164 patients. During the follow-up period, 4 (2.4%) patients developed liver cirrhosis and in 5 (3%) patients hepatocellular carcinoma (HCC) occurred out of 164 patients. HBsAg seroconversion occurred in one patient (0.6%).

 

 

Conclusion: Tenofovir can be used safely and successfully in those patients that were naive, experienced with immune modulators and/or antivirals, HBeAg-positive, and HBeAg-negative patients.

Files
EISSN 2148-5607